Mascarenhas, J., Kuykendall, A. T., Bradley, T. J., Scott, B. L., Yang, Y., Lennox, A., Mudge-Riley, M., Ho, J., Eid, J. E., Otoukesh, S. (2026). Updated protocol: IMPROVEMF, a phase 1b trial of imetelstat (IME)+ ruxolitinib (RUX) in patients (pts) with intermediate (INT)-1/2 or high-risk (HR) myelofibrosis (MF).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps6604